The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments-Reference-Cited by-同舟云学术

The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments

Published:2022-02 Issue:1 Volume:20 Page:e25-e38
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Mesci Aruz^ORCID,Isfahanian Naghmeh^ORCID,Dayes Ian^ORCID,Lukka Himu,Tsakiridis Theodoros^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference106 articles.

1. Projected estimates of cancer in Canada in 2020;Brenner;CMAJ,2020

2. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

3. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials;Roach;J Urol,2006

4. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer;Daly;World J Urol,2020

5. Duration of androgen suppression in the treatment of prostate cancer;Bolla;N Engl J Med,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy;Communications Biology;2023-09-08

2. Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech;Cancers;2023-03-28

4. Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer;Frontiers in Oncology;2022-07-07

5. Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study;Frontiers in Oncology;2022-03-29